Skip to main content
SpringerLink
Log in

Antiproliferative effects of ZD0473 (AMD473) in combination with 5-Fluorouracil or SN38 in human colorectal cancer cell lines

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Purpose: ZD0473 (AMD473) [cis-amminedichloro(2-methylpyridine) platinum(II)] is a novel platinum agent of proven activity in vitro against a variety of human tumor-derived cell lines even with intrinsic or acquired resistance to CDDP. The aim of this study is to provide the basis for a rational design of ZD0473-based combination in colon cancer. Experimental design: We evaluated the cytotoxic effect of ZD0473 administered alone or in combination with 5-Fluorouracil (5FU) or SN38 in a panel of sensitive and 5FU-resistant colorectal cell lines (HT29/HT29-5FUR and LoVo/LoVo-5FUR). We analyzed four sequential schedules of administration: ZD0473 → 5FU, 5FU → ZD0473, ZD0473 → SN38 and SN38 → ZD0473. MTT-assay and isobologram analyses were performed to determine the synergism/antagonism. Results: The pattern of response towards ZD0473, administered as single agent, was similar in all cases and independent of the 5FU-resistance phenotype (IC50 from 48.1 to 76.6 μM) and/or p53 status. No differences in sensitivity to ZD0473 alone or in combination were observed between DNA-mismatch repair-proficient (HT29/HT29-5FUR) and -deficient (LoVo/LoVo-5FUR) cells. ZD0473 administered prior to 5FU leads to synergistic/additive effect in all cell lines, while the 5FU → ZD047 schedule was only synergistic in HT29 cells. Exposure to ZD0473 prior to SN38 leads to a synergistic/additive schedule in LoVo/LoVo-5FUR cells, while SN38 → ZD0473 schedule was only synergistic in parental cell lines. Conclusions: The combinations of ZD0473 and 5FU or SN38 have shown to be active in sensitive and 5FU-resistant colorectal cell lines when a correct schedule of administration is applied. These results may be further exploited to promote new schedules of administration for advanced colorectal cancer treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. O'Dwyer PJ, Johnson SW, Hamilton TC: Cisplatin and its analogues In: Pharmacology of Cancer Chemotherapy. Chapter 19, Section 5, DeVita

  2. Rixe O, OrtúzarW, Alvarez M, Parker R, Reed E, Paull K, Fojo T: Oxaliplatin, Tetraplatin, Cisplatin and Carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen Panel. Biochem Pharmacol 52: 1855–1865, 1996

    Google Scholar 

  3. Kelland LR: Preclinical perspectives on platinum resistance. Drugs 59(Suppl 4): 1–8, 2000

    Google Scholar 

  4. Judson IR, Kelland LR: New developments and approaches in the platinum arena. Drugs 59(Suppl 4): 29–36, 2000

    Google Scholar 

  5. Kelland LR, Sharp SY, O'Neill CF, Raynaud FI, Beale PJ, Judson IR: Mini-review: Discovery and development of platinum complexes designed to circumvent cisplatin resistance. J Inorg Biochem 77(1/2): 111–115, 1999

    Google Scholar 

  6. Cvitkovic E, Chaney SG: Oxaliplatin:Anewoption for the treatment of colorectal cancer. Sem Oncol 35(2) Suppl 5, 1998a

  7. Cvitkovic E. Ongoing and unsaid on oxaliplatin: The hope. Br J Cancer 77(Supl 4): 8–11, 1998b

    Google Scholar 

  8. Machover D, Díaz-Rubio E, DeGramont A, Schilf A, Gastiaburu JJ, Brienza S, Itzhaki M, Metzger G, N'DawD, Vignoud J, Abad A, Francois E, Gamelin E, Marty M, Sastre J, Seitz F, Ychou M: Two consecutive phase II trials of Oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7: 95–98, 1996

    Google Scholar 

  9. Giachetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic E, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F: Phase III multicenter randomised trial of Oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastasic colorectal cancer. J Clin Oncol 18: 136–147, 2000

    Google Scholar 

  10. Becouarn Y, Gamelin E, Coudert B, Negrier S, Pierga JY Raoul JL, Provencal J, Rixe O, Krisch C, Germa C, Bekraddan M, Mignard D, Mousseau M: Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastasic colorectal cancer patients. J Clin Oncol 19(22): 4195–420, 2001

    Google Scholar 

  11. Plasencia C, Taron M, Martínez E, Rosell R, Abad A: Downregulation of Thymidylate Synthase gene expression after Oxaliplatin administration: Implication for the synergistic activity of sequential Oxaliplatin/5-FU in sensitive and 5FU-resistant cell lines Proc Am Assoc Cancer Res 2735, 2001 (abstract)

  12. Kelland LR, Barnard CDJ: ZD0473. Drugs Fut 23(10): 1062–1065, 1998

    Google Scholar 

  13. Kelland LR, Abel G, Mckeage MJ, Jones M, Goddard PM, Valenti M, Bryant A, Murrer BA, Harrap KL: Preclinical antitumour evaluation of bis-acetato-ammine-dichlorocyclohexylamine platinum (IV): An orally active platinum drug. Cancer Res 53: 2581–2586, 1993

    Google Scholar 

  14. Holford J, Sharp SY, Murrer BA, Abrams M, Kelland LR: In vitrocircumvention of cisplatin resistance by the novel sterically hindered platinum complex ZD0473. Br J Cancer 77(3): 366–373, 1998

    Google Scholar 

  15. Raynoud FI, Boxall FE, Goddard PM, Valenti M, Jones M Murrer BA, Abrams M, Kelland LR: Cis-Amminedichloro(2-methylpyridine) Platinum (II) (ZD0473), a novel sterically hindered platinum complex: In VivoActivity, Toxicology and Pharmacokinetics in mice. Clin Cancer Res 3: 2063–2074, 1997

    Google Scholar 

  16. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD, Howell SB: The role of DNA mismatch repair in platinum drug resistance. Cancer Res 46: 4481–4486, 1996

    Google Scholar 

  17. Fink D, Aebi S, Howell SB: The role of DNA mismatch repair in drug resistance Clin Cancer Res 4: 1–6, 1998

    Google Scholar 

  18. Modrich P: Strand-specific mismatch repair in mammalian cells. J Biol Chem 272: 24727–24730, 1997

    Google Scholar 

  19. Vaisman A, Varchenko M, Umar A: The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: Correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58: 3579–3585, 1998

    Google Scholar 

  20. Plasencia C, Taron M, Abad A, Rosell R: Synergism of Oxaliplatin (OXA) with either 5-Fluorouracil (5-FU) or Topoisomerase I Inhibitor in sensitive and 5FU-resistant cell lines is independent of DNA-mismatch repair and p53 status Proc Am Soc Clin Oncol 204: 793, 2000 (abstract)

    Google Scholar 

  21. Ferreira CG, Tolis C, Giaccone G: p53 and chemosensitivity. Ann Oncol 10: 1011–1021, 1999

    Google Scholar 

  22. Bunz F, Durtriaux A, Lengauer C, Waldman T, Zhang Y, Dillehay L, Williams J, Lenghauer C, Kinzler KW, Vogelstein B: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497–1501, 1998

    Google Scholar 

  23. De Feudis P, Debernardis D, Beccaglia P, Valenti M, Graniela Siré A, Arzani D, Stanzione S, Parodi S, D'Incalci M, Russo P, Broggini M: DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status. Br J Cancer 76: 474–479, 1997

    Google Scholar 

  24. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudeiro PA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ, Kohn KW: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute Anticancer Drug Screen and correlation with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285–4300, 1997

    Google Scholar 

  25. Amundson SA, Myers TG, Fornance AJ: Roles for p53 in growth arrest and apoptosis: Putting on the brakes after genotoxic stress. Oncogene 17: 3287–3299, 1998

    Google Scholar 

  26. Pestell KE, Medlow CJ, Titley CJ, Kelland LR, Walton MI: Characterization of the p53 status, Bcl-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines. Int J Cancer 77(6): 913–918, 1998

    Google Scholar 

  27. Pestell KE, Hobbs SM, Titley JC, Kelland LR, Walton MI: Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. Mol Pharmacol 57 (3): 503–511, 2000

    Google Scholar 

  28. Plasencia C, Rooney PH, Taron M, Martinez-Balibrea E, McLeod HL, Abad A: Chromosomal imbalance maps of human 5FU-resistant colorectal cancer cell lines: Implications in the analysis of 5FU-acquired resistance mechanisms. Int J Oncol 22: 945–953, 2002

    Google Scholar 

  29. Taron M, Plasencia C, Abad A: Preclinical synergy of Oxaliplatin (OXA), Topoisomerase I inhibitor (Topotecan) and 5-Fluorouracil in sensitive and 5-Fluorouracil resistant HT29 cell line. Proc Am Soc Clin Oncol (abstract) 691, 1999

  30. Olsson NO, Leclerc A, Jeannin JF, Martin F:Asimple photometric microassay for the quantitative evaluation of macrophagemediated cytotoxicity on adherent cells. Ann Immunol 133D(3): 245–254, 1982

    Google Scholar 

  31. Alley MC, Scudieron DA, Monks A, Hursey ML, Czerwinski MJ, FinkDL, Abbot BJ, Mayo JG, Shoemaker RH: Feasibility of drug screening with panels of human tumor cell lines using microculture tetrazolium assay. Cancer Res 48: 589–601, 1988

    Google Scholar 

  32. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22: 27–55, 1984

    Google Scholar 

  33. Medina-Gundrum L, Gómez L, Cerna C, Yochmowitz M, Koehler M, Stephens T, Weitman S: ZD0473 exhibits marked in vitroanticancer activity in human tumour specimens. European Conference of Clinical Oncology, October 21, 2001

  34. Stewart DJ, Gelmon KA, Ayers D, Fry D, Douglas L, McIntosh L, Seymour LK: A phase I study of ZD0473 and docetaxel given once every three weeks in patients with advanced refractory cancer. A National Cancer Institute of Canada-Clinical Trials Group Study. 12thAACR-NCI-EORTC, International Conference 2001

  35. Piccart MJ, Lamb H, Vermorken JB. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol 12(9): 1195–1203, 2001

    Google Scholar 

  36. Beamount PO, Moore PJ, Ahmad K, Payne NM, Lee C, Riddick DA. Role of glutathione S-transferases in the resistance of human colon cancer cell lines to Doxorubicin. Cancer Res 58(5): 947–955, 1998

    Google Scholar 

  37. Sharp SY, O'Neill CF, Rogers P, Boxall FE, Kelland LR. Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to Oxaliplatin. Eur J Cancer 38: 2309–2315, 2002

    Google Scholar 

  38. Sharp SY, O'Neill CF, Boxall F, Rogers P, Stephens T, Kelland LR. Non-cross resistance between oxaliplatin and ZD0473 in acquired cisplatin-resistant colon and ovarian carcinoma cell lines. Clin Cancer Res (Suppl.) 6: 4537s, 2000

  39. Latorre A, DeLuna M, Catino A, Cruccitta E, Sambiasi D, Guida M, Misino A, Lorusso V: Epithelial ovarian cancer: Second and third line chemotherapy. Int J Oncol 21(1): 179–186, 2002

    Google Scholar 

  40. Rogers P, Boxall FE, Allot CP, Stephens TC, Kelland LR: Sequence-dependent synergism between the new generation platinum aguent ZD0473 and placitaxel in cisplatin-sensitive and-Resistant human ovarian carcinoma cell lines. Eur J Cancer 38: 1653–1660, 2002

    Google Scholar 

  41. Kanzawa F, Akiyama Y, Saijo N, Nishio K: In vitroeffects of the combination of ZD0473 and gemcitabine in human lung cancer cells. AACR-NCI-EORTC, Conference, 2001

  42. O'Dwyer PJ, Stevenson JO, Redlinger M, Sun W Giantonio B, Hahn S, Algazy K, Burnite M, Garcia-Vargas J, Roberts DW, Oliver R: Pharmacokinetic study of the novel platinum agent ZD0473 in combination with gemcitabine-A phase I study in patients with advanced cancer. AACR-NCI-EORTC Conference, 2001

  43. Van Moersel CJ, Pinedo HM, Veerman G, Vermorken JB, Postmus PE, Peters GJ: Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small cell lung cancer cell lines. Br J Cancer 80: 981–990, 1999

    Google Scholar 

  44. Raymond E, Lawrence R, Izbicka E, Faivre S, Von Hoff D: Activity of Oxaliplatin against human tumor colony-forming units. Clin Cancer Res 4 (4): 1021–1029, 1998

    Google Scholar 

  45. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E: Cellular and molecular pharmacology of Oxaliplatin. Mol Cancer Therap 1: 227–235, 2002

    Google Scholar 

  46. Zeghari-Squalli N, Raymond E, Ctvikovic E, Goldwasser F: Cellular pharmacology of the combination of the DNA Topoisomerase I inhibitor SN38 and the Dyaminocyclohexane Platinum derivative Oxaliplatin. Clin Cancer Res 5: 1189–1196, 1999

    Google Scholar 

  47. Goldwasser F, Bozec L, Zeghari-Squalli N, Misset JL: Cellular pharmacology of the combination of Oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line. Anticancer Drugs 10: 195–201, 1999

    Google Scholar 

  48. Sheithauer W, Komek GV, Marczell A, Salem G, Karner J, Kovats E, Burger D, Greimer R, Pidlich J, Schneeweiss B, Raderer M, Rosen H, Depisch D: Combined Irinotecan and Oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorinpretreated colorectal cancer J Clin Oncol 17: 902–906, 1999

    Google Scholar 

  49. Guichard S, Arnould S, Hennebelle I, Bugat R, Canal P: Combination of oxaliplatin and irinotecan on human colon cancer cell lines: Activity in vitroand in vivo. Anticancer Drugs 12: 1–11, 2001

    Google Scholar 

  50. Zunino F, Perego P, Pilotti S, Pratesi G, Supino R, Arcamone F: Role of apoptotic response in cellular resistance to cytotoxic agent. Pharmacol Ther 73: 177–185, 1997

    Google Scholar 

  51. Branch P, Masson M, Aquilina G, Bignami M, Karran P: Spontaneous development of drug resistance: Mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. Oncogene 19: 6138–3145, 2000

    Google Scholar 

  52. Mathe G, Kidani Y. Segiguchi M, Eriguchi M, Fredj F, Peytavin G, Misset GL, Brienza S, de Vassals F, Chenu E: Oxalatoplatinum or 1-OHP, a third generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 43: 237–250, 1989

    Google Scholar 

  53. Cosaert J, Quoix E: Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer 87: 825–833, 2002

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Service and Laboratory of Molecular Biology, Hospital Universitari Germans Trias i Pujol, Spain

    Carmen Plasencia, Albert Abad, Eva Martinez-Balibrea & Miquel Taron

Authors
  1. Carmen Plasencia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Albert Abad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eva Martinez-Balibrea
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miquel Taron
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Plasencia, C., Abad, A., Martinez-Balibrea, E. et al. Antiproliferative effects of ZD0473 (AMD473) in combination with 5-Fluorouracil or SN38 in human colorectal cancer cell lines. Invest New Drugs 22, 399–409 (2004). https://doi.org/10.1023/B:DRUG.0000036682.99818.71

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:DRUG.0000036682.99818.71

Search

Navigation